BCYC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.08M

+90.83%

-0.936

+14.88%

7.25M

-27.38%

-0.817

-7.2%

5.76M

+97.36%

-0.903

-20.76%

Estimates Revision

The market is revising Upward the revenue expectations for Bicycle Therapeutics plc (BCYC) for FY2025, with the revenue forecasts being adjusted by 8.8% over the past three months. During the same period, the stock price has changed by 5.18%.

Revenue Estimates for FY2025

Revise Upward

+8.8%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.37%

In Past 3 Month

Stock Price

Go Up

+5.18%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.29 USD with a low forecast of 11.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

2 Hold

0 Sell

Strong Buy

Current: 7.310

Low

11.00

Averages

22.29

High

44.00

Current: 7.310

Low

11.00

Averages

22.29

High

44.00

Truist

Hold

initiated

$10

2025-11-24

Reason

Truist

Price Target

$10

2025-11-24

initiated

Hold

Reason

Truist initiated coverage of Bicycle Therapeutics with a Hold rating and $10 price target. The time to market and ultimate market potential remains uncertain for Zele, pending further visibility from the Phase 2/3 Duravelo-2 trial, particularly as Padcev continues to entrench as a widely adopted standard of care, the analyst tells investors in a research note. Truist adds that it sees broader value from Bicycle's pipeline, including BT5528, and the radiopharma franchise, though these programs remain early in development and are unlikely to yield meaningful near-term contribution.

RBC Capital

Leonid Timashev

Outperform -> Sector Perform

downgrade

$27 -> $11

2025-10-31

Reason

RBC Capital

Leonid Timashev

Price Target

$27 -> $11

2025-10-31

downgrade

Outperform -> Sector Perform

Reason

RBC Capital analyst Leonid Timashev last night downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27, following the Q3 report. The company's pipeline programs are taking more time to reach inflection points, the analyst tells investors in a research note. RBC thinks Bicycle's near-term updates may not provide substantial enough data to de-risk its programs and drive share upside. As such, the firm moves to the sidelines pending greater visibility into the path forward for zelenectide and BT5528.

Citizens JMP

Reni Benjamin

Outperform

maintain

$10 -> $12

2025-10-31

Reason

Citizens JMP

Reni Benjamin

Price Target

$10 -> $12

2025-10-31

maintain

Outperform

Reason

Citizens JMP analyst Reni Benjamin raised the firm's price target on Bicycle Therapeutics to $12 from $10 and keeps an Outperform rating on the shares. Bicycle reported Q3 financial results and updated corporate milestones, including regulatory feedback regarding dose selection for the pivotal Duravelo-2 now expected in 1Q26, the analyst tells investors in a research note. Bicycle shares have upside from current levels, with the zele pivotal trial enrolling, multiple partnerships secured, and a strong cash position of $648.3M, the firm says.

RBC Capital

Leonid Timashev

Outperform -> Sector Perform

downgrade

$27 -> $11

2025-10-30

Reason

RBC Capital

Leonid Timashev

Price Target

$27 -> $11

2025-10-30

downgrade

Outperform -> Sector Perform

Reason

RBC Capital analyst Leonid Timashev downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27.

Citizens JMP

Outperform

NULL

downgrade

$22 -> $10

2025-08-12

Reason

Citizens JMP

Price Target

$22 -> $10

2025-08-12

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Bicycle Therapeutics to $10 from $22 and keeps an Outperform rating on the shares. Bicycle recently reported Q2 financial results and updated corporate milestones, and Citizens believes that the main value-driving event for this year is the selection of the optimal go-forward dose of zelenectide pevedotin in the pivotal Duravelo-2 trial. Bicycle shares may still provide upside from current levels, the analyst tells investors in a research note.

Oppenheimer

Jay Olson

Outperform

downgrade

$48 -> $44

2025-08-11

Reason

Oppenheimer

Jay Olson

Price Target

$48 -> $44

2025-08-11

downgrade

Outperform

Reason

Oppenheimer analyst Jay Olson lowered the firm's price target on Bicycle Therapeutics to $44 from $48 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 financial results with $2.9M collaboration revenue, $71.0M R&D and $18.5M G&A expenses, and $721.5M cash. A notable update was the announcement of cost-reduction initiatives aimed at lowering operating costs by 30%, mostly through a 25% workforce reduction, which will further extend the financial runway into 2028. Oppenheimer views the cost-reduction initiative as a prudent measure to sharpen focus on near-term priorities, particularly the upcoming zelenectide pevedotin Phase 2/3 Duravelo-2 dose selection updates in Q4.

Valuation Metrics

The current forward P/E ratio for Bicycle Therapeutics PLC (BCYC.O) is -2.13, compared to its 5-year average forward P/E of -6.77. For a more detailed relative valuation and DCF analysis to assess Bicycle Therapeutics PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.77

Current PE

-2.13

Overvalued PE

-2.46

Undervalued PE

-11.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.23

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.41

Undervalued EV/EBITDA

-8.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

42.15

Current PS

0.00

Overvalued PS

67.48

Undervalued PS

16.83

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BCYC News & Events

Events Timeline

No data

News

7.5

12-16Businesswire

Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium

7.5

12-16Newsfilter

Bicycle Therapeutics Signs 15-Year Contract with UK NDA for 400 Tonnes of Reprocessed Uranium

7.0

12-11PRnewswire

Bicycle Therapeutics Under Investigation, ADR Price Drops 7.88%

People Also Watch

Frequently Asked Questions

What is Bicycle Therapeutics PLC (BCYC) stock price today?

The current price of BCYC is 7.31 USD — it has decreased -0.27 % in the last trading day.

What is Bicycle Therapeutics PLC (BCYC)'s business?

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

What is the price predicton of BCYC Stock?

What is Bicycle Therapeutics PLC (BCYC)'s revenue for the last quarter?

Bicycle Therapeutics PLC revenue for the last quarter amounts to 11.73M USD, increased 338.49 % YoY.

What is Bicycle Therapeutics PLC (BCYC)'s earnings per share (EPS) for the last quarter?

Bicycle Therapeutics PLC. EPS for the last quarter amounts to -0.85 USD, increased 14.86 % YoY.

What changes have occurred in the market's expectations for Bicycle Therapeutics PLC (BCYC)'s fundamentals?

How many employees does Bicycle Therapeutics PLC (BCYC). have?

Bicycle Therapeutics PLC (BCYC) has 305 emplpoyees as of December 17 2025.

What is Bicycle Therapeutics PLC (BCYC) market cap?

Today BCYC has the market capitalization of 507.08M USD.